BillionToOne (BLLN) vs Celcuity (CELC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
BillionToOne is the larger company by market cap ($4.52 billion vs $3.22 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLLN | CELC |
|---|---|---|
| Share price | $95.75 | $65.78 |
| Market cap | $4.52B | $3.22B |
| 1-day change | -4.19% | -7.68% |
| YTD return | +17.00% | -34.05% |
| 1-year return | — | +33.66% |
| 5-year return | — | +261.43% |
| P/E ratio (TTM) | 151.98 | — |
| Forward P/E | 64.48 | — |
| EPS (TTM) | $0.63 | $-4.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $305.11M | — |
| Revenue growth (YoY) | +99.97% | — |
| Net income (latest FY) | $7.45M | — |
| Gross margin | 68.32% | — |
| Operating margin | 5.25% | — |
| Net margin | 2.44% | — |
| 52-week high | $150.44 | $151.02 |
| 52-week low | $61.96 | $45.03 |
| Distance from 52-week high | -36.35% | -56.44% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +34.73% | +138.54% |
| Average volume | 695.65K | 1.19M |
| Shares outstanding | 42.64M | 48.93M |
| Employees | 713 | 155 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BillionToOne
BLLN stock →BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
Health Care · Medical Specialities · 713 employees
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Health Care · Medical Specialities · 155 employees
BLLN vs CELC FAQ
Which is bigger, BillionToOne or Celcuity?
BillionToOne (BLLN) is larger, with a market capitalization of $4.52B compared with $3.22B for Celcuity (CELC).
Are BillionToOne and Celcuity in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.